Beijing Luzhu Biotech Co Ltd

Beijing Luzhu Biotechnology Co., Ltd. is a biotechnology company that develops human vaccines and therapeutic biologics to prevent and control infectious diseases and to treat cancer and autoimmune diseases in Mainland China. Its pipeline includes LZ901, a recombinant herpes zoster vaccine with a submitted biologics license application (BLA); K3, a recombinant human anti-tumor necrosis factor-alpha monoclonal antibody injection that has completed a Phase 1 trial for autoimmune diseases such as rheumatoid arthritis, ankylosing spondylitis, and plaque psoriasis; and K193, a bispecific antibody injection in Phase 1 for B cell leukemia and lymphoma. Preclinical candidates include recombinant vaccines for varicella, RSV, HSV-1, and HSV-2, as well as K333 and K1932 bispecific antibodies. The company also offers immunoreagents and diagnostic kits, and was incorporated in 2001, headquartered in Beijing, China.